Editorials

Pfizer’s $5 Billion GLP-1 Bet Looks Like a Catch-Up Trade
Author Image

Jack Breaks

Feb 6, 2026

Pfizer’s acquisition of Metsera comes at a steep price: nearly three times the company’s valuation just eight months earlier. After abandoning its own GLP-1 program, Pfizer is paying a large premium to reenter the obesity market late. But the deal raises a question of whether Pfizer already lost?

Racing the Mineral Bottleneck: EMAT’s Bet on Going Public Early
Author Image

Cayden Liu

Feb 4, 2026

The rush toward AI infrastructure and electrification has turned critical minerals into one of the most crowded trades of 2026. EMAT’s decision to enter public markets through a reverse merger offers speed and exposure, but little of the trust traditionally built through an IPO.

Qualcomm 2025 M&A Recap: Big Strides in AI, IoT, and Auto
Author Image

Yessica Jain

Feb 3, 2026

In a single year, Qualcomm completed six acquisitions across AI and semiconductor infrastructure. The message is clear: as its traditional modem business faces long-term erosion, Qualcomm is racing to transform itself from a communications specialist into a fully integrated AI platform company.

The EA Buyout: A $55 Billion Bet on the Future of Gaming, or a Debt-Fueled Mistake?
Author Image

Shaurya Vohra

Feb 2, 2026

Leveraged buyouts thrive on predictability. Video games do not. EA’s $55 billion take-private deal forces one of the most creatively volatile industries to operate under one of the most financially rigid ownership structures.

The $5.3 Billion Roller Coaster: How Jana Partners and Travis Kelce Plan to Save Six Flags
Author Image

Samuel Regelman

Nov 8, 2025

When a company with $5.3 billion in debt and a 47% stock collapse attracts a hedge fund and an NFL star, it’s not charity, it’s strategy. Jana Partners and Travis Kelce are betting they can turn Six Flags from a sinking relic into a comeback story worth watching.

The $2.1 Billion Sleep Deal: Alkermes’s Biggest Gamble Yet
Author Image

Yessica Jain

Nov 6, 2025

Alkermes just placed a $2.1 billion bet on sleep with a sleep drug few investors saw coming. Alkermes isn’t just buying Avadel, it’s buying time and maybe the future of mental health medicine.

The $300 Billion Warning: Why Luxury's Summer Collapse Signals Crisis Ahead
Eliazar Marchenko's Profile Image

Eliazar Marchenko

Sep 21, 2025

LVMH’s sharpest sales drop since 2008 is more than a fashion story. Luxury’s downturn has historically foreshadowed recessions, and today it coincides with weakening confidence, asset stress, and slowing global demand.

The Congressman Betting Against America: What Tim Moore's TZA Trades Really Signal
Eliazar Marchenko's Profile Image

Eliazar Marchenko

Sep 10, 2025

As Vice Chairman of the Financial Services Committee, Tim Moore helps set the rules for America’s markets. He is also betting millions that those markets, and the small businesses they support, are about to fail.

Musk’s $17 Billion Bet: How SpaceX Just Bought Its Way Into America’s Wireless Oligopoly
Eliazar Marchenko's Profile Image

Eliazar Marchenko

Sep 9, 2025

Elon Musk just paid $17 billion for spectrum licenses, most experts call worthless, 100 times the going rate. On paper, the deal looks insane. Through Washington’s lens, it’s the smartest move SpaceX has ever made.

Load More

Load More